ALK-Abelló A/S, the Danish allergy immunotherapy specialist, reported 15% organic revenue growth in the third quarter of 2026, driven primarily by a 35% surge in tablet sales. Operating profit rose 9% to DKK 469 million, delivering an EBIT margin of 27% for the quarter and 28% for the first nine months. The company confirmed its full-year outlook, which had already been upgraded on 7 October 2026, reinforcing management's confidence in sustained momentum across all sales regions.

Key Points

  • ALK-Abelló A/S (0OIR) — Danish allergy and anaphylaxis treatment specialist
  • Q3 2026 revenue grew 15% to DKK 1,764 million, with tablet sales reaching DKK 999 million, up 35%
  • Full-year revenue growth guidance of 16–17% in local currencies confirmed; EBIT margin expected at around 27%
  • Investors may be watching progress on the ACARIZAX® China regulatory filing, the peanut allergy tablet FDA application, and the neffy® nasal spray international roll-out

ALK-Abelló Tablet Sales Surge 35% in Q3 2026, Paediatric Roll-Out a Key Driver

Tablet revenue reached DKK 999 million in Q3 2026, up from DKK 737 million in Q3 2025, representing growth of 35% in local currencies. The announcement attributes the performance to the ongoing paediatric roll-out, with Europe growing 33%, North America 32%, and International markets 47%. Partially offsetting this strength, SCIT/SLIT drop sales declined 6% to DKK 527 million, impacted by lower subcutaneous immunotherapy shipments to China. Sales of Anaphylaxis and other products edged up 1% to DKK 238 million, with anaphylaxis sales specifically rising 5% in isolation.

Nine-Month Free Cash Flow Rises to DKK 1,192 Million as Net Debt Position Turns Negative

For the first nine months of 2026, ALK-Abelló reported revenue of DKK 5,330 million, representing 17% growth in local currencies and 16% in reported currency. EBIT for the nine-month period reached DKK 1,484 million, with a margin of 28%. Free cash flow improved materially to DKK 1,192 million, compared with DKK 836 million in the equivalent prior-year period. The company's net debt to EBITDA ratio stood at negative 0.7 at the end of September 2026, indicating a net cash position, which the disclosure suggests provides meaningful financial flexibility heading into 2027.

ACARIZAX® China Filing, Catalent Manufacturing Expansion and neffy® Roll-Out Advance ALK's Allergy+ Strategy

ALK and its Chinese partner GenSci expect to file for regulatory approval of the house dust mite tablet ACARIZAX® in China in H1 2027, following a successful phase 3 clinical trial outcome. The neffy® nasal adrenaline spray has launched in 14 markets, with Canada and a 1 mg formulation for young children in Germany progressing. ALK has also entered a partnership with Zuellig Pharma for select Southeast Asian markets. Separately, ALK expanded its agreement with Catalent to secure long-term access to Zydis® tablet technology and increase annual manufacturing capacity to 1.1 billion units from the early 2030s.

ALK-Abelló Confirms 2026 Full-Year Revenue Growth Guidance of 16–17% in Local Currencies

The company confirmed its full-year 2026 financial outlook, which was upgraded on 7 October 2026. Revenue is expected to grow 16–17% in local currencies, with tablets identified as the primary growth driver across all regions and product lines. The EBIT margin is guided at around 27%, principally reflecting operating leverage from revenue expansion. Investors may be watching whether the FDA provides feedback on ALK's peanut allergy tablet phase 3 development plans, as the company has submitted a clinical trial application and is awaiting regulatory guidance before initiating the trial.